Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
NCT05888922

Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

Led by Industrial Farmacéutica Cantabria, S.A. · Updated on 2026-05-12

520

Participants Needed

13

Research Sites

106 weeks

Total Duration

On this page

Sponsors

I

Industrial Farmacéutica Cantabria, S.A.

Lead Sponsor

B

Bioskin GmbH

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn about oral minoxidil 1mg in the treatment of women with androgenetic alopecia, a type of hormone-imbalanced hair loss. The main questions to answer are to know about that minoxidil 1mg is as effective as minoxidil 2% topical solution (comparator product) and is more effective than placebo; and to ensure treatment with oral minoxidil is safe. Participants will be assigned randomly to receive one of the following treatment combinations: * the test product (oral minoxidil 1 mg, once/day) and the vehicle solution (vehicle means it looks like the comparator product, but it does not contain an active ingredient, 2 times/day), or * the placebo tablet (placebo means it looks like the test product, but it does not contain an active ingredient, once/day) and the comparator product (2% minoxidil solution, 2 times/day), or * the placebo tablet (once/day) and the vehicle solution (2 times/day). The clinical trial will take up to 36 weeks. During this time, patients will come to the clinical trial centre for 5 times for examinations and will be called by phone twice. At the visits, the following examinations will be performed: photos of the hair will be taken to determine hair density, assessment of changes in scalp hair growth, measurement of blood pressure, pulse, and body temperature, a physical examination, blood withdrawal to determine any abnormalities in the blood, urine sampling and analysis, performance of ECG, and evaluation of hypertrichosis (i.e., excessive hair growth over the body). Furthermore, patients will be asked daily whether they had experienced any side effects or took any new medications (or changed the dose of a known medication) or underwent any medical procedure. Also, women of childbearing potential must undergo pregnancy tests in blood and urine.

CONDITIONS

Official Title

Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female patients aged 18 years or older with generally good health and no history of cardiovascular or other significant diseases
  • Diagnosed with female androgenetic alopecia (FAGA) showing decreased hair density in the centroparietal scalp area (Sinclair Scale 2-4)
  • Hair color that provides enough contrast with the scalp, confirmed by TrichoLab Virtual Tattoo technology at screening
  • Signed informed consent indicating understanding of the trial procedures
  • Negative pregnancy tests at screening and baseline for women of childbearing potential (WOCBP)
  • WOCBP must be permanently sterile or use highly effective birth control throughout the trial and for at least 2 weeks after last treatment
  • Stable use of gestagens with antiandrogen properties as contraceptives allowed if used for at least 6 months before baseline and continued during trial
  • Willingness to keep the same hairstyle, hair color, and hair care routine during the trial
  • Willingness to maintain consistent facial and body hair removal habits throughout the trial
  • Ability and willingness to comply with scheduled visits, treatment plan, lab tests, and daily electronic diary recording using own device and internet
Not Eligible

You will not qualify if you...

  • Allergy or hypersensitivity to minoxidil or any product components
  • Pregnancy or desire to become pregnant during the trial
  • Breastfeeding or nursing women
  • Diagnosed or untreated hypertension (blood pressure >150/95 mmHg) or history of cardiovascular disease
  • Scalp dermatological disorders in the target area that may interfere with treatment or assessments, such as active moderate/severe seborrheic dermatitis, infections within past 3 months, active atopic dermatitis or psoriasis within past 6 months, other types of alopecia or pathological hair loss within past 3 months
  • History of hair transplant surgery or hair extensions/weaving within past 6 months
  • Abnormal laboratory or ECG results indicating illness
  • Kidney function abnormalities (creatinine and eGFR above normal limits)
  • Significant history of serious diseases that may interfere with trial objectives
  • Use of topical scalp treatments affecting hair growth within specified timeframes before baseline (e.g., minoxidil, hormones, corticosteroids, laser, PRP)
  • Use of certain systemic medications or therapies affecting hair growth within specified timeframes before baseline (e.g., vasodilators, 5 alpha reductase inhibitors, retinoids, beta blockers, antiandrogens, minoxidil, prostaglandins, biotin)
  • Previous scalp radiation or chemotherapy treatments
  • Participation in other investigational drug trials within 30 days or 5 half-lives before baseline
  • History of drug or alcohol dependency
  • Probable non-compliance or inability to understand the trial and provide informed consent
  • Close relationship with the investigator or employment by sponsor or trial center
  • Institutionalization due to legal or regulatory orders

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

Fachklinik Bad Bentheim Klinisches Studienzentrum

Bad Bentheim, Germany

Actively Recruiting

2

CRC - Charité Universitätsmedizin Berlin Clinical Research Center for Hair and Skin Science

Berlin, Germany

Actively Recruiting

3

emovis by Futuremeds GmbH

Berlin, Germany

Actively Recruiting

4

Rosenpark Reasearch GmbH

Darmstadt, Germany

Not Yet Recruiting

5

Privatpraxis Dr. Hilton & Partner

Düsseldorf, Germany

Terminated

6

Klinik für Dermatologie, Venerologie und Allergologie - Universitätsmedizin Frankfurt

Frankfurt, Germany

Actively Recruiting

7

Dermaticum -Dr. med. Mario Bittar und Kollegen

Freiburg im Breisgau, Germany

Actively Recruiting

8

Eurofins bioskin - Research Center Dermatology

Hamburg, Germany

Actively Recruiting

9

Klinische Forschung Karlsruhe GmbH

Karlsruhe, Germany

Actively Recruiting

10

Siteworks - Prüfzentrum Lohne

Löhne, Germany

Active, Not Recruiting

11

Zentrale Studienkoordination für innovative Dermatologie (ZiD) Klinik für Hautkrankheiten Universitätsklinikum Münster (UKM)

Münster, Germany

Withdrawn

12

Haut-und Lasercentrum - Dr. Tanja Fischer und Kollegen

Potsdam, Germany

Actively Recruiting

13

TRIDERM Study Site Dermatological practice Dr. Leitz and colleagues

Stuttgart, Germany

Actively Recruiting

Loading map...

Research Team

A

Ana López-Ballesteros

CONTACT

J

Juan José Andrés Lencina

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here